Ricolinostat (ACY-1215)

For research use only. Not for use in humans.

目录号：S8001 别名： Rocilinostat

Ricolinostat (ACY-1215) Chemical Structure

CAS No. 1316214-52-4

Ricolinostat (ACY-1215, Rocilinostat) 是一种选择性HDAC6抑制剂，无细胞试验中IC50为5 nM，作用于HDAC6比作用于HDAC1/2/3(I型HDACs)选择性高10倍以上，对HDAC8具有微弱的作用活性，对HDAC4/5/7/9/11， Sirtuin1和Sirtuin2具有最小的作用活性。Ricolinostat (ACY-1215) 可抑制细胞增殖并促进凋亡。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1566.47	现货
5mg	RMB 900.21	现货
50mg	RMB 4664.38	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ricolinostat (ACY-1215) 发表文献53篇：

Science, 2020, 369(6510)eaas8995

PubMed: 32943500 ( click the link to review the publication )

Elife, 2021, 10e63810

PubMed: 33835029 ( click the link to review the publication )

J Inflamm Res, 2021, 14:1473-1485

PubMed: 33883923 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16751

PubMed: 34180140 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(3)1341

PubMed: 33572814 ( click the link to review the publication )

Breast Cancer Res Treat, 2021, 186(1):37-51

PubMed: 33452951 ( click the link to review the publication )

Oncol Lett, 2021, 22(3):680

PubMed: 34345305 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3734

PubMed: 33322608 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:689

PubMed: 32984302 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 20

PubMed: 32435850 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(14):2595-2611

PubMed: 32792859 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2020, 319(6):F1003-F1014

PubMed: 33103445 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):21

PubMed: 32178737 ( click the link to review the publication )

Histol Histopathol, 2020, 18237

PubMed: 32572875 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:610

PubMed: 32754596 ( click the link to review the publication )

bioRxiv, 2020, 10.1101/2020.12.20.423672

PubMed: None ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Cancer Res, 2019, 79(21):5482-5489

PubMed: 31311810 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14849

PubMed: 31390677 ( click the link to review the publication )

Front Pharmacol, 2019, 10:653

PubMed: 31244662 ( click the link to review the publication )

Biomed Pharmacother, 2019, 117:109166

PubMed: 31255993 ( click the link to review the publication )

Ann Transl Med, 2019, 7(1):2

PubMed: 30788349 ( click the link to review the publication )

Int J Oncol, 2019, 55(2):499-512

PubMed: 31268156 ( click the link to review the publication )
Life Sci, 2019, 238:116976

PubMed: 31634464 ( click the link to review the publication )

Neurochem Res, 2019, 44(11):2460-2469

PubMed: 31571096 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Anticancer Res, 2019, 39(12):6731-6741

PubMed: 31810938 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

J Pathol, 2018, 246(2):141-153

PubMed: 29876933 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 30050135 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

J Biol Chem, 2018, 293(6):1976-1993

PubMed: 29259132 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):844-854

PubMed: 29749542 ( click the link to review the publication )

Br J Cancer, 2018, 119(10):1278-1287

PubMed: 30318510 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1280-1290

PubMed: 29483217 ( click the link to review the publication )

Biochem Pharmacol, 2018, 155:316-325

PubMed: 30028995 ( click the link to review the publication )

Biomed Pharmacother, 2018, 97:818-824

PubMed: 29112935 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(8):962-973

PubMed: 28737768 ( click the link to review the publication )

Oncogene, 2017, 10.1038/onc.2016.495

PubMed: 28114281 ( click the link to review the publication )

ACS Chem Biol, 2017, 12(8):2139-2148

PubMed: 28628306 ( click the link to review the publication )

Dis Model Mech, 2017, 10(10):1245-1252

PubMed: 28819043 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):51-60

PubMed: 28110187 ( click the link to review the publication )

J Periodontol, 2017, 88(1):e12-e23

PubMed: 27562218 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4280-4289

PubMed: 28270494 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1369-1382

PubMed: 28496307 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103797-103814

PubMed: 29262601 ( click the link to review the publication )
Oncotarget, 2016, 7(7):7715-31

PubMed: 26735339 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Tumour Biol, 2015, 36(12):9661-5

PubMed: 26150340 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0481

PubMed: 25552369 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

特性

ACY-1215作用于4名健康捐献者的PHA刺激的PBMCs，与pan-HDAC抑制剂SAHA相比，具有更低的细胞毒性。

靶点

HDAC6 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)	HDAC3 ^[1] (Cell-free assay)	HDAC1 ^[1] (Cell-free assay)	HDAC8 ^[1] (Cell-free assay)
4.7 nM	48 nM	51 nM	58 nM	100 nM

体外研究

ACY-1215是一种异羟肟酸类衍生物。ACY-1215作用于HDAC1, HDAC2, 和 HDAC3 (I型 HDACs)效果分别低12，10, 和 11倍。ACY-1215最低活性作用于(IC50>1μM) HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1,和 Sirtuin2,对HDAC8(IC50=0.1μM)具有轻微的作用活性。ACY-1215作用于T细胞毒性的IC50值为2.5μM。ACY-1215作用于骨髓（BM）环境，克服BMSCs和细胞因子赋予的肿瘤细胞生长和存活。ACY-1215与Bortezomib联用，诱导协同抗MM活性。ACY-1215在非常低的剂量时，诱导强有力的α-tubulin乙酰化，只有在较高剂量时，触发组蛋白H3和H4组蛋白赖氨酸的乙酰化，证实其对HDAC6活性的特定抑制效果。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
A-172	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TGWVExyqCwTR?=	M1rvdVI1NzR6IHi=	NV3VPZVTcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>?	NVfoNnN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOVA{PDBpPkK2NVUxOzRyPD;hQi=>
U87MG	NV\jfpk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ntT\|ExyqCwTR?=	NXzqe4RiOjRxNEigbC=>	MXPpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	MonYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNUCzOFAoRjJ4MUWwN\|QxRC:jPh?=
Hbl-1	M4TL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2jlUVQ5KGh?	MljpTWM2OD1zLk[g{txO	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNkK3NEc,OjZzMU[yO\|A9N2F-
OCI-Ly10	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmX0OFghcA>?	MYrJR\|UxRTBwOTFOwG0>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNkK3NEc,OjZzMU[yO\|A9N2F-
Riva	M1TKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlvQOFghcA>?	MnvVTWM2OD1{LkKg{txO	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNkK3NEc,OjZzMU[yO\|A9N2F-
Su-DHL2	NXnP[3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1jvV\|Q5KGh?	MmC0TWM2OD1\|LkOg{txO	MmPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMU[yO\|AoRjJ4MUG2NlcxRC:jPh?=
OCI-Ly1	NF\aVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmLKOFghcA>?	MljvTWM2OD1{LkSg{txO	MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMU[yO\|AoRjJ4MUG2NlcxRC:jPh?=
OCI-Ly7	NHLNdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUe0PEBp	NHWwPFFKSzVyPUGuNkDPxE1?	NXvJUnkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVYzPzBpPkK2NVE3OjdyPD;hQi=>
Su-DHL4	MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIXNR4Y1QCCq	MoD5TWM2OD12Lkeg{txO	MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMU[yO\|AoRjJ4MUG2NlcxRC:jPh?=
Su-DHL6	M1nBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3nLW\|Q5KGh?	M4PFV2lEPTB;Mz6yJO69VQ>?	M3zmNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG2NlcxLz5{NkGxOlI4ODxxYU6=
Hbl-2	NIPMWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M33wflQ5KGh?	MUjJR\|UxRTFwOTFOwG0>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNkK3NEc,OjZzMU[yO\|A9N2F-
Jeko-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{XiUlQ5KGh?	M2nvXWlEPTB;MT61JO69VQ>?	M2SwPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG2NlcxLz5{NkGxOlI4ODxxYU6=
Jvm-2	M2HnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYPYeXJXPDhiaB?=	MXTJR\|UxRTRwMDFOwG0>	M2Hm[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG2NlcxLz5{NkGxOlI4ODxxYU6=
Rec-1	NVnQVGFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUm0PEBp	M1;EVGlEPTB;Mj6zJO69VQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNkK3NEc,OjZzMU[yO\|A9N2F-
CCL-119	NXHmfVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIftdHo1QCCq	Mm\rTWM2OD1zLkeg{txO	M37JXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG2NlcxLz5{NkGxOlI4ODxxYU6=
H9	NEfkR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYO0PEBp	M2rqOGlEPTB;MT6yJO69VQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNkK3NEc,OjZzMU[yO\|A9N2F-
HH	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVm0PEBp	MoLlTWM2OD1{LkWg{txO	NXPrd2pWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVYzPzBpPkK2NVE3OjdyPD;hQi=>
Sup-T1	MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIf2SlI1QCCq	MlzvTWM2OD1zLk[g{txO	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNkK3NEc,OjZzMU[yO\|A9N2F-
MM.1S	MlHSSpVv[3Srb36gRZN{[Xl?	M4jRNFAuPc7:TR?=	NFfUWnY3KGh?	M2nT[Ylv[3KnYYPld{Bi[2W2eXzheIVlKM7zLYT1ZpVtcW5?	M1f4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[yO\|YxLz5{MkK2Nlc3ODxxYU6=
MM.1S	MUTGeY5kfGmxbjDBd5NigQ>?	MV[wMlI2NzIQvF2=	M{npPVE5KGh?	NFi3RllqdmO{ZXHz[ZMh[WOndInsZZRm\CEQsT30eYJ2dGmw	MmHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{NkK3OlAoRjJ{Mk[yO\|YxRC:jPh?=
MM.1R	Mo\FSpVv[3Srb36gRZN{[Xl?	MWKwMlI2NzIQvF2=	MUGxPEBp	M4TUUIlv[3KnYYPld{Bi[2W2eXzheIVlKM7zLYT1ZpVtcW5?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4Mke2NEc,OjJ{NkK3OlA9N2F-
RPMI8226	NEX2XJZHfW6ldHnvckBCe3OjeR?=	M37oclAvOjVxMd88US=>	NHHSe\|IyQCCq	MkfJbY5kemWjc3XzJIFk\XS7bHH0[YQh\|rFvdIXieYxqdg>?	NXPsZoJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlI4PjBpPkKyNlYzPzZyPD;hQi=>
MM.1S	NFjBeoJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mo\xNE05\|ryP	MYK0PEBp	NXPLSoJ1\GWlcnXhd4V{KE2PLXPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M{jod\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[yO\|YxLz5{MkK2Nlc3ODxxYU6=
OPM1	Mo\KR4VtdCCYaXHibYxqfHliQYPzZZk>	NHXZcG4xNTkQvF2=	MXq0PEBp	NGK5OXll\WO{ZXHz[ZMhVU1vY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NIrKZ4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2Nlc3OCd-MkKyOlI4PjB:L3G+
RPMI	MlzaR4VtdCCYaXHibYxqfHliQYPzZZk>	MUmwMVjPxE1?	M1n6XFQ5KGh?	Mn7G[IVkemWjc3XzJG1ONWOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M3;2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[yO\|YxLz5{MkK2Nlc3ODxxYU6=
MM.1R	NUjPdGE1S2WubDDWbYFjcWyrdImgRZN{[Xl?	Mn3yNE05\|ryP	NE\GPFI1QCCq	MWjk[YNz\WG\|ZYOgUW0u[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4Mke2NEc,OjJ{NkK3OlA9N2F-
LR5	NHPrcIFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFnoN5ExNTkQvF2=	MmnQOFghcA>?	MUHk[YNz\WG\|ZYOgUW0u[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MlnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{NkK3OlAoRjJ{Mk[yO\|YxRC:jPh?=
OPM2	NXfacVg4S2WubDDWbYFjcWyrdImgRZN{[Xl?	NFzaSXAxNTkQvF2=	MUS0PEBp	M{fRcIRm[3KnYYPld{BOVS2lZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Mo\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{NkK3OlAoRjJ{Mk[yO\|YxRC:jPh?=
Sf9	M4nFR2Z2dmO2aX;uJIF{e2G7		NE\Mbm8yOCCvaX7z	NWO0d45HUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBPNXSncn3pcoFtKEeVVD30ZYdo\WRiSFTBR\|Yh\XiycnXzd4VlKGmwIGPmPUBk\WyuczD1d4lv\yCIVGOgZZMhe3Wkc4TyZZRmKHC{ZXnuZ5Vj[XSnZDDmc5IhOTBibXnud{Bnd2yub4fl[EBjgSC\|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRib4\ldkA{OCCvaX7zMEBKSzVyIE2gNE4xODR5IN88UU4>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEOyOEc,OjhyM{izNlQ9N2F-
Sf9	Mmq0SpVv[3Srb36gZZN{[Xl?		M{LQelE2KG2rboO=	NGfqVopKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCKRFHDOkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgd4Y6KGOnbHzzJJV{cW6pIFLvZ{1NgXNvKFHjLU1CVUNiYYOgd5Vje3S{YYTlJJBz\WmwY4XiZZRm\CCob4KgNVUhdWmwczDmc4xtd3enZDDifUB{fWK\|dILheIUh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOlAhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjByOTFOwG0v	Mnz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MECxN\|AoRjJ7NUCwNVMxRC:jPh?=
Sf9	NGnZOI5HfW6ldHnvckBie3OjeR?=		M1jFZ\|E2KG2rboO=	NH\NcmpKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJGMufGW{bXnuZYwhUGm\|LYTh[4dm\CCKRFHDN{9PNXSncn3pcoFtKEeVVD30ZYdo\WRiTlPPVlIhMDN7NTD0c{A1QDlicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNidYPpcochSm:lLVz5d{0pSWNrLVHNR{BieyC\|dXLzeJJifGVicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGluIFnDOVAhRSByLkCzO{DPxE1w	NEfDcZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWwNFE{OCd-Mkm1NFAyOzB:L3G+
Sf9	NVmxeFJMTnWwY4Tpc44h[XO\|YYm=		NFXMcXYyOCCvaX7z	NXrlUnNKUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBENXSncn3pcoFtKE[OQVeteIFo\2WmIFjERWMzKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgeZNqdmdiRmTTJIF{KHO3YoP0doF1\SCycnXpcoN2[mG2ZXSg[o9zKDFyIH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIH;2[ZIhOzBibXnud{whUUN3MDC9JFAvODR6IN88UU4>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEOyOEc,OjhyM{izNlQ9N2F-
Sf9	NWXLS3ZyTnWwY4Tpc44h[XO\|YYm=		M{DWS\|ExKG2rboO=	M3ju[2lvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5icnXjc41jcW6jboSgR{11\XKvaX7hcEBHVEGJLVjpd{11[WepZXSgTGRCSzFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{B2e2mwZzDGWHMh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EBnd3JiMUCgcYlveyCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgc5ZmeiB\|MDDtbY5{NCCLQ{WwJF0hOC5yNUig{txONg>?	M3SyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I1Lz5{OECzPFMzPDxxYU6=
Sf9	NEjU[GVHfW6ldHnvckBie3OjeR?=		NXXwXGd2OTVibXnudy=>	M1rYdmlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigdoVkd22kaX7hcpQhcHWvYX6gR{11\XKvaX7hcEBJcXNvdHHn[4VlKEiGQVOyJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lkh[2WubIOgeZNqdmdiQn;jMWx6ey1qQXOpMWFOSyCjczDzeYJ{fHKjdHWgdJJmcW6ldXLheIVlKG[xcjCxOUBucW6\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODZ4IN88UU4>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyMEGzNEc,Ojl3MECxN\|A9N2F-
Sf9	NGeye\|dHfW6ldHnvckBie3OjeR?=		NYXrUVlTOTVibXnudy=>	NUnhXXpWUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBz\WOxbXLpcoFvfCCqdX3hckBENXSncn3pcoFtKE[OQVevTIl{NXSjZ3fl[EBJTEGFMTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy\|IIXzbY5oKEKxYz3MfZMuMEGlKT3BUWMh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiNkCgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|LDDJR\|UxKD1iMD6xJO69VS5?	NY\NU\|lIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NFAyOzBpPkK5OVAxOTNyPD;hQi=>
BCP-ALL	M4\uSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2D0PVczKGi{cx?=	NVzsT\|lvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkOSLVHMUEBk\WyuczDk[ZJqfmWmIH\yc40heGG2aXXueEAyKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{OTFOwG0v	M2\aU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
BCP-ALL	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		MljuO\|IhcHK\|	M{nxWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJEWC2DTFygZ4VtdHNiZHXybZZm\CCocn;tJJBifGmnboSgOEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPTRizszNMi=>	MnXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
BCP-ALL	NUj5c\|llS3m2b4TvfIlkcXS7IHHzd4F6		MYe3NkBpenN?	MofMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmNRNUGOTDDj[YxteyCmZYLpeoVlKG[{b32gdIF1cWWwdDCyJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE42QCEQvF2u	MlHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
RPMI8226	MU\DfZRwfG:6aXPpeJkh[XO\|YYm=		NEfjTVM4OiCqcoO=	MonXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNE[4JO69VS5?	NEG1NY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS0N\|A4QCd-Mk[0OFMxPzh:L3G+
SEM	MmrRR5l1d3SxeHnjbZR6KGG\|c3H5		NYD0cnhtPzJiaILz	NWnySmdRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS54MTFOwG0v	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SUP-B15	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		NF\VW5g4OiCqcoO=	M2HGZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWWC2EMUWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkmyJO69VS5?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
RPMI18226	NELwdGxEgXSxdH;4bYNqfHliYYPzZZk>		M1jKeVczKGi{cx?=	Mo\rR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnBOUTF6MkK2JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT65O{DPxE1w	MorYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
HL60	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		MkfRO\|IhcHK\|	MoL3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvOzZizszNMi=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
HL60	NEjxNI9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkTEOFghcHK\|	M4rJ[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB2ODDodpMhcW5icILld4Vv[2Vib3[gTmFMOiCrbnjpZol1d3JiQ2nUMVM5PyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFIvPTRizszNMi=>	NVG4eFRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFAyOTVpPkK5PVQxOTF3PD;hQi=>
K562	NEDZUGhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NYL2eXdzPDhiaILz	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIlvKHC{ZYPlcoNmKG:oIFrBT\|IhcW6qaXLpeI9zKEO\VD2zPFch[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTCyMlU1KM7:TT6=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl2MEGxOUc,Ojl7NECxNVU9N2F-
HEL	M{LU[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml;hOFghcHK\|	M2TJdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFXMJINmdGy\|IHHmeIVzKDR6IHjyd{BqdiCycnXz[Y5k\SCxZjDKRWszKGmwaHnibZRweiCFWWStN\|g4KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNk42PCEQvF2u	M4[3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUSwNVE2Lz5{OUm0NFEyPTxxYU6=
KCL22	NVj5UmdNS3m2b4TvfIlkcXS7IHHzd4F6		NYOzbGpIPzJiaILz	MmLtR5l1d3SxeHnjbZR6KGGpYXnud5QhcW2jdHnubYIuemW\|aYP0ZY51KGi3bXHuJGtEVDJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy5\|ODFOwG0v	Ml;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
U266	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NGrsOHU4OiCqcoO=	NVf1NmNrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTJ4NjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW\|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwNUKg{txONg>?	NITUfpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
SUP-B15	M1[5d2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NGTZSXk4OiCqcoO=	NILQdYREgXSxdH;4bYNqfHliYXfhbY5{fCCrbXH0bY5q[i2{ZYPpd5RidnRiaIXtZY4hW1WSLVKxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOuOVQh\|ryPLh?=	MmDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
KCL22	NIrnVHJEgXSxdH;4bYNqfHliYYPzZZk>		M1fhXFczKGi{cx?=	NX7MO\|lmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0OOMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Lke1JO69VS5?	M2nsXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
HL60	M1zTO2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEHtTWE1QCCqcoO=	NV;EZoJ7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFMvPzVizszNMi=>	NEjX[5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NFEyPSd-Mkm5OFAyOTV:L3G+
K562	MmL5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVr1XI43PDhiaILz	NYLkVXRbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFMvPzVizszNMi=>	NYWwNJY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFAyOTVpPkK5PVQxOTF3PD;hQi=>
HEL	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4jXcVQ5KGi{cx?=	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiHTDDj[YxteyCjZoTldkA1QCCqcoOgZpkhS0ONLUigZZN{[XluIFnDOVAhRSB\|Lke1JO69VS5?	NVrQfGR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFAyOTVpPkK5PVQxOTF3PD;hQi=>
BCP-ALL	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		MXW3NkBpenN?	MnzTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmNRNUGOTDDj[YxteyCmZYLpeoVlKG[{b32gdIF1cWWwdDCzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE41PSEQvF2u	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
MV4-11	M{\sdmZ2dmO2aX;uJIF{e2G7	M1LzS\|ExODBibl2=	M3m2bFYhcHK\|	Mni4TY5pcWKrdHnvckBw\iCKRFHDNU8zNzNiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIHH0JFExODBibl2gZYZ1\XJiNjDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M1[1e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NESzNFc5Lz5{NkS0N\|A4QDxxYU6=
TC32	NVrSZYFReUiWUzDhd5NigQ>?			Ml;EdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	NIryOG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MW\xTHRUKGG\|c3H5			MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	NV\xdZVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	M1P0U5FJXFNiYYPzZZk>			MnPXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MnnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NF3GeGdyUFSVIHHzd4F6			MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	M3rTbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NXPCdmlUeUiWUzDhd5NigQ>?			Mn70dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M4OydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	M3vsZpFJXFNiYYPzZZk>			MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NWnJeoJkeUiWUzDhd5NigQ>?			M2jmeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NEG0c2hyUFSVIHHzd4F6			NHTHcIdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NFzBO289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NVuy[pdteUiWUzDhd5NigQ>?			M{TRW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M4m3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NH3TSWtyUFSVIHHzd4F6			M172cpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	NUPlTmlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MnXxdWhVWyCjc4PhfS=>			M3K1eZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NYrTOY95RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	NVzCTXI6eUiWUzDhd5NigQ>?			NHzscGNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	NITHZWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	Mk\IdWhVWyCjc4PhfS=>			M3XWVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	MlG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MUnxTHRUKGG\|c3H5			NVrNZotoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NVzUXmV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MXrxTHRUKGG\|c3H5			MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NEjyPFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NEfkNXByUFSVIHHzd4F6			M171XpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NHH1SHhyUFSVIHHzd4F6			NFXFdllyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NEDyTZFyUFSVIHHzd4F6			NGrRbo5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MnjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HL60	NF;wT4lHfW6ldHnvckBie3OjeR?=	NY\jdY9lOC5zIITvJFExKHWP	Mo\aNlQhcHK\|	MWLJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJGhNPjBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNmfHmuLXHsdIhiKHS3YoXsbY4h\XiycnXzd4lwdiCjdDCwMlEhfG9iMUCgeW0h[W[2ZYKgNlQhcHK\|IHL5JIludXWwb3Lsc5Qh[XO\|YYm=	NEK5[Hg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
SEM	M1nFbGZ2dmO2aX;uJIF{e2G7	NYP0d\|FsOC5zIITvJFExKHWP	M4rNeVI1KGi{cx?=	NF\4SGpKdmirYnn0bY9vKG:oIFjERWM3KGmwIHj1cYFvKFOHTTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBi[2W2eXytZYxxcGFidIXieYxqdiCneIDy[ZN{cW:wIHH0JFAvOSC2bzCxNEB2VSCjZoTldkAzPCCqcoOgZpkhcW2vdX7vZoxwfCCjc4PhfS=>	NX;q[3p2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
SUP-B15	MV\GeY5kfGmxbjDhd5NigQ>?	Mle5NE4yKHSxIEGwJJVO	Ml7ENlQhcHK\|	NVXsZVlbUW6qaXLpeIlwdiCxZjDISGFEPiCrbjDpcYF1cW6rYj3y[ZNqe3SjboSgbJVu[W5iU2XQMWIyPSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWxvYXzwbIEhfHWkdXzpckBmgHC{ZYPzbY9vKGG2IECuNUB1dyBzMDD1UUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveEBie3OjeR?=	M1nPUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
HL60	MY\GeY5kfGmxbjDhd5NigQ>?	MlX5NE4yKHSxIEGwJJVO	NXvXWYE5OjRiaILz	MVTJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJGhNPjBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNmfHmuLXjpd5RwdmViSEOg[ZhxemW\|c3nvckBifCByLkGgeI8hOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZZN{[Xl?	NUTrVmRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
SEM	M4niSWZ2dmO2aX;uJIF{e2G7	NVXqPZB5OC5zIITvJFExKHWP	NWHBSYxvOjRiaILz	MV\Jcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJHNGVSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWxvaHnzeI9v\SCKMzDlfJBz\XO\|aX;uJIF1KDBwMTD0c{AyOCC3TTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdDDhd5NigQ>?	MlnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
SUP-B15	NWntd\|VXTnWwY4Tpc44h[XO\|YYm=	NYSxcHllOC5zIITvJFExKHWP	MlvtNlQhcHK\|	NWjzXY1QUW6qaXLpeIlwdiCxZjDISGFEPiCrbjDpcYF1cW6rYj3y[ZNqe3SjboSgbJVu[W5iU2XQMWIyPSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWxvaHnzeI9v\SCKMzDlfJBz\XO\|aX;uJIF1KDBwMTD0c{AyOCC3TTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdDDhd5NigQ>?	M3fVdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
HL60	M1;N[WZ2dmO2aX;uJIF{e2G7	M4W4TFAvOSC2bzCxNEB2VQ>?	MkfONlQhcHK\|	MUnJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJGhNPjBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ4xm[X[nZDDQRXJRKGW6cILld5Nqd25iYYSgNE4yKHSxIEGwJJVOKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91KGG\|c3H5	NGHIWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
SEM	MmTqSpVv[3Srb36gZZN{[Xl?	NYLm[WlXOC5zIITvJFExKHWP	MoXtNlQhcHK\|	NYDUT451UW6qaXLpeIlwdiCxZjDISGFEPiCrbjDoeY1idiCVRV2gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[2ynYY\l[EBRSVKSIHX4dJJme3Orb36gZZQhOC5zIITvJFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHzd4F6	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SUP-B15	NGLTRXdHfW6ldHnvckBie3OjeR?=	MWOwMlEhfG9iMUCgeW0>	M4XiW\|I1KGi{cx?=	Mo\zTY5pcWKrdHnvckBw\iCKRFHDOkBqdiCrbXH0bY5q[i2{ZYPpd5RidnRiaIXtZY4hW1WSLVKxOUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClbHXheoVlKFCDUmCg[ZhxemW\|c3nvckBifCByLkGgeI8hOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZZN{[Xl?	MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
SEM	MlfvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkTmNlQhfG9iN{KgbJJ{	NH7QS2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPFUUBk\WyuczDheEBKSzVyIITvJFIhfGmvZYOgTWM2OCCjZoTldkAzPCC2bzC3NkBpenNiYomgeJJ6eGGwIHX4Z4x2e2mxbjDt[ZRpd2R?	NXLsWG9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
HEL	NFr1eYNE\WyuIHP5Z4xmKGG\|c3H5	NFvvfmYyKHSxIEGwJJVO	MXO0PEBpenN?	NHX3ZnRE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJTUxiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEGgeI8hOTBidV2gZYZ1\XJiNEigbJJ{KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSg[oxwfyCleYTvcYV1enl?	NH3Zeog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NFEyPSd-Mkm5OFAyOTV:L3G+
SEM	NInVTGVHfW6ldHnvckBie3OjeR?=		MkK0NVghcHK\|	Mmq0TY5pcWKrdHnvckBw\iCKRFHDOkBqdiCqdX3hckBUTU1iY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZYdoemW\|b33lJIFk[3WvdXzheIlwdiCjdDDJR\|UxKGGodHXyJFE5KGi{czDifUBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yaXOgcYV1cG:m	NFzRelU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
SEM	NFLy[nZHfW6ldHnvckBie3OjeR?=	M2\vVVEvPiC3TR?=	M3v3U\|E5KGi{cx?=	MmjGTY5pcWKrdHnvckBw\iCKRFHDOkBqdiCqdX3hckBUTU1iY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZYdoemW\|b33lJIFk[3WvdXzheIlwdiCjdDCxMlYhfU1iYX\0[ZIhOThiaILzJIJ6KE[DQ2OgZY5idHm\|aYO=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SH-SY5Y	M1L5R2Z2dmO2aX;uJIF{e2G7	M3fKRlAvOSC2bzCxJJVO	NXrUeGxtOjRiaILz	NVvoPFhmUW6qaXLpeIlwdiCxZjDISGFEPiCrbjDoeY1idiCVSD3TXVV[KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHHj[ZR6dGG2aX;uJI9nKGGucHjhMZR2[nWuaX6gZZQhOC5zIITvJFEhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NFrTNoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECyPFYyPid-M{CwNlg3OTZ:L3G+
SH-SY5Y	M{X6Z2Z2dmO2aX;uJIF{e2G7	M3Lx[VAvOSC2bzCxJJVO	MWCyOEBpenN?	MnfvTY5pcWKrdHnvckBw\iClbHHzd{AyKEiGQVOgbY4hcHWvYX6gV2guW1l3WTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KDBwMTD0c{AyKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M1jmZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEK4OlE3Lz5\|MECyPFYyPjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-α-tubulin / Ac-Histone H4 ; PubMed: 31015208 Blood Adv Ricolinostat promotes the accumulation of acetylated (Ac) α-tubulin. MM cells were treated with the indicated concentrations of ricolinostat for 24 hours. Protein expression was measured by immunoblotting. Survivin / P21 / CDC2 / p53 / p-p53(S392) / Cyclin A2 / Cyclin B1; PubMed: 30050135 Cell Death Dis Western blot analysis of G2/M phase cell cycle regulatory-proteins for 48 h Bax / Bim / Bcl2 / Cleaved caspase-3 / Cleaved caspase-9 / Cleaved PARP; PubMed: 30050135 Cell Death Dis Western blot analysis of apoptosis regulatory-proteins for 48 h PI3K(p85) / AKT / p-AKT(S473) / PRAS40 / Rag C / mTOR / p-mTOR / ERK / p-ERK; PubMed: 30050135 Cell Death Dis ACY-1215 treatment inhibited PI3K/AKT/mTOR and ERK signaling protein levels in ESCC EC109 and TE-1 cell lines for 48 h. Ac-β-catenin(K49) / p-β-catenin / β-catenin; PubMed: 25546293 ACS Chem Biol Time-course immunoblot analysis of human NPCs treated with an HDAC6 inhibitor. Human NPCs were treated with HDAC6 inhibitor ACY-1215 at 5 μM for the times points indicated and the lysates immunoblotted with antibodies against β-catenin, Ac-Lys49-β-catenin, phos-Ser45 and phos-Ser33, Ser37, and Thr41. β-actin is using shown as loading control.	31015208 30050135 25546293
Immunofluorescence	β-tubulin / β-catenin; PubMed: 25546293 ACS Chem Biol Immunofluorescence staining for β-catenin treated with HDAC6 inhibitor in human NPCs. Cells were treated with 5 μM ACY-1215 or DMSO for 18 h and imaged with anti-β-catenin antibody (green), anti-β-tubulin antibody (red), and Hoechst 33342 (blue). Scale bar, 20 μm. Quantification of β-catenin levels at the membrane represent two independent experiments with three fields of view each at 20× magnification. Error bars indicate standard deviation. and ** denote significance at p < 0.01 and p < 0.0001, respectively (unpaired t test).	25546293
Growth inhibition assay	Cell viability; PubMed: 31015208 Blood Adv Ricolinostat decreases MM cell viability. A panel of MM cell lines was treated with the indicated concentrations of ricolinostat for 72 hours. Cell viability was measured by MTT assay.	31015208

体内研究

ACY-1215与Bortezomib 联用，作用于两个浆细胞瘤模型和弥散性MM模型，抑制肿瘤生长，并延长生存，没有显著的不利影响。比单独使用具有更显著的抗MM 活性。ACY-1215易被肿瘤组织吸收。此外，药物不会在肿瘤组织中累积，处理24小时后，血液细胞和肿瘤组织的乙酰化的α-tubulin平行下降。^[1]

激酶实验： ^[1]	- 合并 HDAC 酶促实验: ACY-1215在实验 Buffer [50 mM HEPES, pH 7.4, 100 mM KCl, 0.001% Tween-20, 0.05% BSA, 和20 μM三羧甲基磷酸（TCEP）] 中溶解，然后稀释到终浓度的6倍。HDAC酶在实验Buffer中稀释到终浓度的1.5倍，与ACY-1215预温育10分钟，然后加入底物。通过滴定曲线测定，用于每种酶的FTS（HDAC1，HDAC2，HDAC3和HDAC6）和MAZ-1675（HDAC4，HDAC5，HDAC7，HDAC8，和HDAC9）量等于米氏常数（K_m）。使用0.3μM 测序等级胰蛋白酶将FTS或MAZ-1675在实验 Buffer中稀释到终浓度的6倍。底物/胰蛋白酶混合物添加到酶/化合物混合物中，实验板震荡60秒，然后置于SpectraMax M5酶标仪上。监测酶促反应中的7-氨基-4-甲氧基香豆素在30分钟内的释放，肽底物中赖氨酸侧链的脱乙酰化，计算反应的线性速率。
细胞实验： [1]	- 合并 Cell lines: MM cell lines, patient MM cells, and PBMCs Concentrations: ~8 μM Incubation Time: 48 hours Method: PBMCs from healthy donors are isolated and stimulated with 2.5 μg/mL of phytohemagglutinin (PHA) for 48 hours in the presence of increasing concentrations of ACY-1215. DNA synthesis is measured by tritiated thymidine uptake. CD4⁺T cells are purified from human blood with the Rosette Sep negative-selection kit. Cells are stimulated by CD3/CD28 Dynabeads for 7 days in the presence of compounds. Cell viability is assessed using alamarBlue. MM cells (2-3 × 10⁴cells/well) are incubated in 96-well culture plates with medium and different concentrations of ACY-1215, bortezomib, and/or recombinant IL-6 (10 ng/mL) or insulin-like growth factor-1 (IGF-1; 50 ng/mL) for 24 hours at 37°C, and tritiated thymidine incorporation is measured. (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: MM移植瘤SCID小鼠模型 Dosages: 50 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[1] Santo L, et al. Blood, 2012, 119(11), 2579-2589.

溶解度 (25°C)

体外	DMSO	86 mg/mL (198.38 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+ 40% PEG 300+ 5% Tween 80+ 50% ddH2O	0.62mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ricolinostat (ACY-1215) SDF

分子量	433.5
化学式	C₂₄H₂₇N₅O₃
CAS号	1316214-52-4
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Rocilinostat

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02632071	Completed	Drug: ACY-1215\|Drug: Nab-paclitaxel	Metastatic Breast Cancer\|Breast Carcinoma	Columbia University\|Acetylon Pharmaceuticals Incorporated\|National Cancer Institute (NCI)	March 1 2016	Phase 1
NCT01583283	Active not recruiting	Drug: ACY-1215\|Drug: lenalidomide\|Drug: Dexamethasone	Multiple Myeloma	Celgene	July 12 2012	Phase 1\|Phase 2
NCT01323751	Completed	Drug: ACY-1215	Multiple Myeloma	Celgene\|The Leukemia and Lymphoma Society	July 2011	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What would you suggest to obtain a clear solution?
回答：
S8001 ACY-1215 can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 5 mg/ml clearly while it in 1% DMSO/30% polyethylene glycol/1% Tween 80 at 30 mg/ml is a suspension for oral administration. Please note that the precipitation will go out from the clear solution after stayed for about half an hour, So it is recommended to prepare the solution just before use.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

泛HDAC抑制剂

Panobinostat (LBH589) : Pan-HDAC inhibitor, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

定制您的化合物库

Ricolinostat (ACY-1215)

客户使用Selleck生产的Ricolinostat (ACY-1215) 发表文献53篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ricolinostat (ACY-1215) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品